Assignment of Core versus Antenna Fucosylation Types in Protein N-Glycosylation via Procainamide Labeling and Tandem Mass Spectrometry.

Fucosylation is an important feature of protein N-glycosylation as it has been reported to influence the efficacy of therapeutic proteins and as a potential disease biomarker. A common approach for characterizing protein N-glycans is to analyze the native glycans via tandem mass spectrometry (MS). However, tandem MS analysis of native N-glycans typically results in proton migration, which in turn leads to fucose residue migration from the glycan core to the antenna and vice versa. This phenomenon ultimately leads to ambiguous assignment of N-glycan fucosylation. Although the use of specific fucosidases has been successfully employed for assigning fucosylation, such strategies are often too cumbersome, expensive, and time-consuming for routine N-glycan analysis. As an alternative, we explore the influence of labeling N-glycans with procainamide hydrochloride to inhibit fucose migration during tandem MS analysis. The labeled N-glycan pool was separated and analyzed using ultraperformance liquid chromatography and a hydrophobic interaction liquid chromatography column coupled to a quadrupole time-of-flight mass spectrometer (UPLC-HILIC-QTOF-MS). The observation of the m/z 587.3 core fucose diagnostic peak corresponding to [GlcNAc + Fucose + Procainamide + H](+) in the tandem MS data of fucosylated N-glycans rapidly verifies core fucosylation while its absence signifies antennae fucosylation. This unique approach is here validated with human IgG (for core fucosylation) and human alpha-1-acid-glycoprotein (for antenna fucosylation). We further present a useful application toward the rapid verification of fucosylation types in a therapeutic protein (Rituximab).

[1]  Jun-Tao Ji,et al.  Decreased Core-Fucosylation Contributes to Malignancy in Gastric Cancer , 2014, PloS one.

[2]  Akira Okazaki,et al.  Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics. , 2007, Journal of biotechnology.

[3]  Kazuya Yamano,et al.  Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. , 2004, Biotechnology and bioengineering.

[4]  B. Ernst,et al.  False sugar sequence ions in electrospray tandem mass spectrometry of underivatized sialyl-Lewis-type oligosaccharides , 1997 .

[5]  H. Matsumoto,et al.  Fucosylation Is a Promising Target for Cancer Diagnosis and Therapy , 2012, Biomolecules.

[6]  K. Shitara,et al.  Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma , 2004, Cancer Research.

[7]  F. Wold,et al.  Effects of the protein matrix on glycan processing in glycoproteins , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  Shinji Hosoi,et al.  Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC , 2006, Biotechnology and bioengineering.

[9]  D. Harvey Collision-induced fragmentation of negative ions from N-linked glycans derivatized with 2-aminobenzoic acid. , 2005, Journal of mass spectrometry : JMS.

[10]  Naoko Yamane-Ohnuki,et al.  Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. , 2005, Journal of immunological methods.

[11]  Angela M Zivkovic,et al.  Simultaneous and extensive site-specific N- and O-glycosylation analysis in protein mixtures. , 2011, Journal of proteome research.

[12]  J. Lowe Glycosylation, Immunity, and Autoimmunity , 2001, Cell.

[13]  R. Aster Core fucosylation and IgG function in NAIT. , 2014, Blood.

[14]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[15]  K. Shitara,et al.  Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism , 2004, Clinical Cancer Research.

[16]  Masako Wakitani,et al.  Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. , 2006, Journal of biochemistry.

[17]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[18]  S. Becht,et al.  Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS. , 2011, Journal of pharmaceutical and biomedical analysis.

[19]  Akira Okazaki,et al.  Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.

[20]  K. Shitara,et al.  Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen Density , 2005, Clinical Cancer Research.

[21]  A. Helenius,et al.  Intracellular functions of N-linked glycans. , 2001, Science.

[22]  Masakazu Toi,et al.  A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients , 2007, Clinical Cancer Research.

[23]  Naoko Yamane-Ohnuki,et al.  Production of therapeutic antibodies with controlled fucosylation , 2009, mAbs.

[24]  M. Novotny,et al.  Resolution of the branched forms of oligosaccharides by high-performance capillary electrophoresis. , 1994, Carbohydrate research.

[25]  André M Deelder,et al.  Mass spectrometry of proton adducts of fucosylated N-glycans: fucose transfer between antennae gives rise to misleading fragments. , 2006, Rapid communications in mass spectrometry : RCM.

[26]  A. Dell,et al.  Structural characterization of the N-glycans of Dictyocaulus viviparus: discovery of the Lewis(x) structure in a nematode. , 2000, Glycobiology.

[27]  Shigeru Iida,et al.  IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. , 2005, Journal of immunological methods.

[28]  R Apweiler,et al.  On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. , 1999, Biochimica et biophysica acta.

[29]  Mary Ann Comunale,et al.  Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular Carcinoma , 2009, Cancer Epidemiology Biomarkers & Prevention.

[30]  P. Pilarski,et al.  Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab , 2008, Clinical medicine. Oncology.

[31]  Hyun Joo An,et al.  Determination of N-glycosylation sites and site heterogeneity in glycoproteins. , 2003, Analytical chemistry.

[32]  Jian Zhang,et al.  The evaluation of a novel approach for the profiling and identification of N-linked glycan with a procainamide tag by HPLC with fluorescent and mass spectrometric detection. , 2010, Journal of pharmaceutical and biomedical analysis.

[33]  M. Betenbaugh,et al.  N-glycan patterns of human transferrin produced in Trichoplusia ni insect cells: effects of mammalian galactosyltransferase. , 2000, Glycobiology.

[34]  Naoko Yamane-Ohnuki,et al.  Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. , 2006, Journal of biochemistry.

[35]  M. Nakano,et al.  Detailed structural features of glycan chains derived from alpha1-acid glycoproteins of several different animals: the presence of hypersialylated, O-acetylated sialic acids but not disialyl residues. , 2004, Glycobiology.

[36]  J. Montreuil Spatial conformation of glycans and glycoproteins , 1984, Biology of the cell.

[37]  K. Olden,et al.  Carbohydrate moieties of glycoproteins. A re-evaluation of their function. , 1982, Biochimica et biophysica acta.

[38]  S. Iida,et al.  Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. , 2007, Molecular immunology.

[39]  A. Varki,et al.  Biological roles of oligosaccharides: all of the theories are correct , 1993, Glycobiology.

[40]  S. Iida,et al.  Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.

[41]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[42]  Kouhei Tsumoto,et al.  Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. , 2004, Journal of molecular biology.

[43]  S. Iida,et al.  Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa , 2006, Clinical Cancer Research.

[44]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.